[Expert consensus on the clinical application of anti-rabies virus monoclonal antibody (2025 edition)].

The anti-rabies virus monoclonal antibody (RmAb) is a novel passive immunization for rabies developed and produced through modern genetic engineering technologies. It specifically binds to the antigenic sites on the G protein of the rabies virus surface, thereby blocking the virus from binding to cellular receptors and exerting a preventive effect. Compared to traditional rabies immunoglobulin, RmAb demonstrates superior advantages in terms of controllable production yield, stable quality, high safety profile, and favorable specific activity. Currently, four RmAb products have been approved for marketing worldwide. In response to the relatively limited understanding of RmAb among clinical practitioners, the Rabies Prevention and Control Committee of the Chinese Preventive Medicine Association and the Animal Injury Treatment Branch of China Association for Disaster and Emergency Rescue Medicine have organized domestic experts to compile this consensus. This document synthesizes the latest evidence, references relevant domestic and international standards, guidelines, and consensus statements, and incorporates expert clinical experience to provide scientific and standardized recommendations for clinical practice.